High purity ginsenoside CK Compound K raw material for stroke support

1. Product Overview 

2. Physicochemical Properties Section

Ginsenoside CK Physicochemical Profile

• Chemical Formula: (boldsymbol{C_{36}H_{62}O_8})
• Molecular Weight: 622.88 g/mol
• CAS No.: 39262-14-1
• Appearance: White to off-white crystalline powder
• Melting Point: 181–183 °C
• Lipophilicity (LogP): 5.50
• Solubility: Soluble in methanol, ethanol, DMSO; slightly soluble in water
• Stability: Hygroscopic; sealed, cool and dry storage required, avoid strong light
• Production Technology: Enzymatic hydrolysis / microbial biotransformation
• Available Specifications: HPLC 98%, 95%, 80%

3. Mechanism Analysis: Neuroprotective Effects Against Cerebral Ischemic Injury

3.1 Stabilize Mitochondrial Dynamics & Energy Metabolism (Core Pathway)

3.2 Inhibit Neuronal Apoptosis & Programmed Cell Death

• Upregulate anti-apoptotic protein Bcl-2, downregulate pro-apoptotic Bax; improve Bcl-2/Bax ratio
• Suppress PTP1B activity, restore IRS1 signaling to block ischemia-triggered neuronal apoptosis
• Inhibit PANoptosis (mixed inflammatory cell death) in ischemia-reperfusion tissue

3.3 Anti-Inflammation & Anti-Oxidative Stress

• Restrain overactivation of microglia in ischemic penumbra
• Downregulate NF-κB pathway, reduce release of TNF-α, IL-1β inflammatory cytokines
• Activate Nrf2/ARE antioxidant pathway, eliminate excess ROS, reduce oxidative damage to nerve cells

3.4 Protect Blood-Brain Barrier Integrity

3.5 Improve Neurological Functional Recovery

Mechanism Summary Sentence (can be extracted for page subtitle):

 

Ginsenoside CK exerts multi-target neuroprotection against cerebral ischemia injury via regulating mitochondrial homeostasis, anti-apoptosis, anti-neuroinflammation and antioxidant activity.

---

 

4. Research In Vivo Data

1. Cerebral Infarct Volume (Dose-dependent efficacy)
    
   After MCAO/R operation, rats treated with Ginsenoside CK showed significantly reduced infarct volume:

• Model group: 24.20% ±1.22%
• CK 10 mg/kg group: 14.60% ±1.25%
• CK 50 mg/kg group: 9.13% ±0.59%
   
  CK reduces infarct volume in a dose-dependent manner (p < 0.001).

2. Neurological Score Improvement

    

   CK administration significantly lowered neurological deficit scores in ischemic rats, indicating alleviated motor and nerve dysfunction caused by focal cerebral ischemia.
3. Neuronal Morphology Observation (Nissl Staining)

    

   Ischemia group presented massive neuron shrinkage, vacuolation and Nissl body loss.

    

   CK treatment group maintained intact neuronal morphology and obviously higher surviving neuron quantity in ischemic penumbra.
4. Mitochondrial Morphology Observation (TEM)

    

   I/R group: severe mitochondrial swelling, cristae rupture, fragmentation.

    

   CK pretreatment: mitochondrial structure tended to be normal, reduced mitochondrial damage.
5. Anti-inflammatory Index

    

   CK effectively suppressed the activation of microglia in cerebral ischemic cortex and decreased levels of pro-inflammatory cytokines in brain homogenate.

5. Application Fields

1. Functional raw materials for brain health dietary supplements
2. Formula development for supporting post-ischemic neurological recovery
3. Nootropic & cerebrovascular support health products
4. Scientific research reagents for neuroscience & cerebral ischemia pharmacology
5. Liposomal, nanocarrier brain-targeted formulation raw materials

6. ---

    

6. Product Advantages 

1. High BBB permeability, direct action on central nervous system
2. Multi-target neuroprotective mechanism for cerebral ischemic cascade injury
3. Produced via controllable enzymatic conversion, stable purity, low impurity
4. Rich published research data on cerebral ischemia models, easy for your product literature development
5. Low acute toxicity, good safety profile for long-term oral formula
6. Customizable purity & bulk packing; COA, HPLC, MS documents supplie

7. ---

    

Recommended dosage: CK 50-200mg/d